Why It Matters

Large non-profit health systems like Ascension face challenges as Congress aggressively reshapes hospital payments, drug pricing programs, and transparency requirements. The core issue is financial survival amid enacted Medicaid cuts.

Ascension is lobbying to preserve rural hospital reimbursements, protect the 340B Drug Pricing Program from restrictive reforms, block site-neutral payment policies, and extend expired telehealth flexibilities. The strategy is defensive and coalition-based, supporting the Bipartisan Health Care Act while opposing the SMART Health Care Act.

Success requires leveraging deep congressional relationships—particularly Mark L. Hayes’ former Senate Finance Committee role—to shape implementation rules within omnibus legislation.

By the Numbers

Ascension spent $550,000 on in-house lobbying in Q3 2025, continuing a two-decade presence exceeding $29.3 million since 2004. The five-person internal team represents $24 million of total spending, supplemented historically by Mehlman Consulting Inc. ($3.12 million) and McDermottPlus LLC ($1.4 million).

The team emphasizes senior congressional experience: Mark L. Hayes anchors the operation with eight years on Capitol Hill as Senate Finance Committee health policy director. Joseph F. Lustig brings seven years of House Democratic experience, while Mark Andrew Howell previously lobbied for the American Hospital Association.

The Agenda

Ascension is lobbying on comprehensive healthcare policy issues with direct financial implications for its 140 hospitals across 19 states.

The organization is pushing for favorable Medicare/Medicaid reimbursement policies, particularly rural hospital protections, while defending the 340B Drug Pricing Program against proposed reforms. Ascension advocates for permanent telehealth flexibilities that expired in September 2025 and opposes site-neutral payment policies that would reduce hospital outpatient reimbursement rates.

Key legislative focuses include the Bipartisan Health Care Act, the 340B ACCESS Act, and broader budget negotiations affecting Medicaid funding. The multi-issue approach reflects coordinated efforts with the broader hospital industry on shared challenges like rural hospital closures and workforce shortages.

Broader Context

Ascension’s Q3 2025 lobbying arrives amid significant healthcare policy turbulence. The industry faces enacted Medicaid cuts threatening rural hospital viability while lawmakers advance site-neutral payment reforms, 340B program oversight, and price transparency mandates with bipartisan support.

Critical pressure points include rural hospital funding uncertainty, the SMART Health Care Act threatening outpatient revenue, intensifying 340B scrutiny through the 340B ACCESS Act, expired telehealth flexibilities, and advancing transparency requirements despite hospital opposition.

Between The Lines

Congress is simultaneously advancing reforms that could benefit and threaten Ascension’s operations. The Senate Finance Committee is considering rural hospital protections through the Bipartisan Health Care Act while advancing site-neutral payment legislation that would slash hospital reimbursement rates.

A Senate HELP Committee hearing challenged whether hospitals pass 340B drug discounts to patients, while joint House subcommittee hearings scrutinized Medicare Advantage authorization delays. The Patients Deserve Price Tags Act requires public pricing disclosures.

Multiple health systems are specifically lobbying on H.R. 1, indicating this omnibus package is the primary legislative vehicle for healthcare priorities this cycle.

Competitive Landscape

Ascension’s advocacy aligns with broader industry efforts across hospital systems. Organizations including the Hospital and Healthsystem Association of Pennsylvania, UPMC, and Sutter Health are filing similar disclosures on Medicare/Medicaid payment reforms and site-neutral payment opposition.

H.R. 1 serves as a critical focal point for coordinated advocacy, where multiple filers are concentrating efforts to secure favorable healthcare provisions. This alignment amplifies industry messaging but means individual health systems must compete for attention within broader coalition efforts.

The Bottom Line

Ascension’s $550,000 Q3 2025 lobbying spend reflects a defensive posture in a shifted political environment where healthcare industry preferences no longer guarantee legislative deference. Despite unified lobbying efforts, the industry failed to prevent over $1 trillion in enacted Medicaid cuts, rural hospitals face an existential crisis with 700 at risk of closure, and telehealth flexibilities expired September 30.

The organization is now focused on shaping implementation of already-enacted policies rather than preventing major legislative setbacks. Success will depend on leveraging congressional relationships to secure favorable regulatory guidance, not blocking unfavorable legislation outright.

Spot something wrong? Report an issue with this article